Clinical Trial Update: Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and efficacy of empagliflozin and sitagliptin versus placebo over 76 weeks in adults with type 2 diabetes; results were compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• Sitagliptin (sitagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2014-07-15